ALPORT SYNDROME EFFICACY & SAFETY TRIAL-1

Alpestria-1

VONAFEXOR is an investigational drug already tested in nine studies in patients with other diseases

1x/day

Orphan Drug Designation for Alport syndrome

ENYO PHARMA aims to **preserve kidney function** and **reverse kidney damage** in **patients with Alport syndrome**

Participant's eligibility



The inclusion criteria for the study are:

- 16*–55 years of age, woman or man
- Alport diagnosis history & genetic test results positive for Alport syndrome
- Mild to moderate loss of kidney function
- Increased albuminuria
- ACEi, ARB or SGLT2i treatment allowed**

About ALPESTRIA-1

- This Phase 2 study will evaluate:
  1. the safety of Vonafexor in Alport syndrome
  2. the benefit of three dose levels of Vonafexor on renal function and biomarkers.
- The study aims at enrolling 20 patients in the US and EU (France, Spain, Germany).
- All participants will receive Vonafexor as oral tablets once daily for 24 weeks then stop the treatment for 12 weeks in the follow-up period.
  No placebo – all subjects will receive study drug.
- Assessments are a mix of 5 site visits, 4 home visits and 4 phone calls, with urine and/or blood sampling.

4 weeks	24 weeks	12 weeks
Patient screening	1st dose → 2nd dose → 3d dose → Vonafexor treatment	No Vonafexor treatment (follow-up)

* 16 years of age for the US
18 years of age for the EU countries

** ACEi: angiotensin converting enzyme Inhibitor
ARB: angiotensin receptor blocker
SGLT2i: sodium-glucose cotransporter-2 inhibitor

For more info about the study, please visit:

For the US: https://clinicaltrials.gov with NCT06425055
For EU: https://euclinicaltrials.eu with 2023-509638-20-00
and https://enyopharma.com or https://alportsyndrome.org

ENYO PHARMA
www.enyopharma.com
Bioserra 1 - Bâtiment B
60 avenue Rockefeller
69008 Lyon, FRANCE